About Cardiosense
About Us
Cardiosense leverages wearable sensing technology, advanced signal processing, and deep learning to transform physiological data into actionable clinical insight.
Founded by engineers and scientists, Cardiosense leverages wearable technology, signal processing, and deep learning to diagnose and assess disease. Our AI platform converts raw physiological data into clinical intelligence, addressing complex cardiovascular challenges. We are now expanding to provide clinicians and patients with tools for precise, proactive heart failure management across all care settings.
Leadership
Eric Meizlish
Chief Executive Officer
John D. Martin, MD, MBA, FACS
Chief Medical Officer
Omer Inan, PhD
Co-founder, Chief Scientific Officer
Andrew Carek, PhD
Co-founder, Chief Technical Officer
Amit Gupta
Co-founder, Chief Strategy Officer
Arezou Azar, PhD
Chief Regulatory & Compliance Officer
Mozziyar Etemadi, MD, PhD
Co-founder, Head of AI
Eric Meizlish joined Cardiosense as CEO in 2025, and he brings experience as a seasoned entrepreneur, operator, and investor in technology enabled businesses. He was a co-founder of Lumere, a leading software and clinical analytics business for hospitals and health systems, and served as its President and Chief Strategy Officer until its acquisition by GHX. At GHX, which offers the healthcare industry's largest supply chain network, he served as the Senior Vice President of Strategy and Corporate Development and was a member of the global leadership team. Following his tenure at GHX, he became CEO of Prendio-BioProcure, a private equity sponsored provider of operational software and services for research-stage biotech companies. He also spent the first several years of his career at Citadel, where he invested in publicly traded Technology, Media, and Telecommunications companies.
Eric is a board member and advisor for several growth stage healthcare technology businesses and serves on the investment committee of Chicago Giving Circle, an organization focused on funding emerging not-for-profits in the Chicago area. He graduated from Yale University in 2004 with a degree in Economics and Mathematics.
Dr. Martin joined Cardiosense as Chief Medical Officer in 2025, bringing decades of experience as a physician and leader of innovative health technology solutions. Most recently, as the Chief Medical Officer of Butterfly Network, he helped bring the transformative digital health ultrasound solution to democratizing medical imaging across the globe.
Dr. Martin is board certified in vascular surgery and a Fellow of the American College of Surgeons, completing residency in general surgery and vascular surgery at Parkland Memorial Hospital in Dallas, Texas. He is currently a Clinical Assistant Professor at the University of Maryland Medical System. He has held multiple leadership positions throughout his career including Chief of Vascular Surgery and Director of Heart and Vascular Services at Anne Arundel Medical Center, President of Cardiology Associates, and Vice President of Physician Operations for MedStar Medical Group. He also served in the United States Air Force for seven years, first as a corpsman and then as a Surgeon during the Gulf War.
Dr. Martin is the founder and President of the Heart Health Foundation and the award-winning Dare to CARE Program. He is the author of many peer reviewed papers and book chapters, a key investigator and trainer in innovative vascular procedures, and holds several patents of his own. He has also developed clinical software used across the country. An often-requested speaker with notable venues including Wall Street Journal Live in Hong Kong, TedMed and HLTH.
Omer Inan is Regents Entrepreneur, and Linda J. and Mark C. Smith Chaired Professor in the School of Electrical and Computer Engineering, and Adjunct Professor in the Coulter Department of Biomedical Engineering, at Georgia Tech. His research, from which Cardiosense's technology was developed, focuses on non-invasive physiological sensing and modulation for human health and performance. He has published more than 380 technical articles in peer-reviewed international journals and conferences and has 18 issued patents.
He has received several major awards for his research including the US National Science Foundation Faculty Early Career (CAREER) award, the US Office of Naval Research Young Investigator award, and the IEEE Sensors Council Early Career award. He is also a Fellow of the IEEE, the American Institute for Medical and Biological Engineering (AIMBE), and the American College of Cardiology. He is currently an IEEE Engineering in Medicine and Biology Society Distinguished Lecturer.
From 2009 to 2013, Omer was the Chief Engineer at Countryman Associates, Inc., a professional audio manufacturer of miniature microphones and high-end audio products for Broadway theaters, theme parks, and broadcast networks. Through his innovation in that role, he received an Academy Award for Technical Achievement from The Academy of Motion Picture Arts and Sciences (The Oscars).
Omer received his BS, MS, and PhD in Electrical Engineering from Stanford in 2004, 2005, and 2009, respectively. While at Stanford as an undergraduate, he was the school record holder and a three-time National Collegiate Athletic Association All-American in the discus throw.
Andrew Carek offers over a decade of biosignal acquisition and analysis experience. He received his B.S. in Electrical Engineering from Clemson University in 2014 and completing his M.S. and Ph.D. degrees at the Georgia Institute of Technology in 2016 and 2019, respectively, where he served in Omer Inan's Research Lab. He also completed his postdoc in the Etemadi Research Lab at Northwestern in 2020. During his time at Georgia Tech, Andrew developed wearable technologies that leverage mechanical signals of the heart to non-invasively derive blood pressure, and his research was foundational to developing the technology that Cardiosense offers today.
Andrew's work has been published in various scientific journals and he has extensive experience presenting at leading conferences. His professional experience also includes research on ubiquitous health monitoring technologies for Microsoft Research. As CTO of Cardiosense, Andrew led the development of the CardioTag™ wireless sensor, designed the cloud-based ML infrastructure, and established robust data pipelines to support clinical studies focused on model training and validation.
Amit Gupta is an entrepreneur and technology leader who has spent over 15 years building and launching data-driven platforms across healthcare, enterprise, and government sectors. Prior to Cardiosense, Amit led product and analytics teams at Yaana Technologies and Ishi Systems, where he launched and scaled enterprise data solutions for Fortune 100 and government clients, including Helix 360, a data fusion platform for national security and public safety agencies. Amit holds a B.S. in Biomedical Engineering from Duke University and an M.B.A. from the Kellogg School of Management at Northwestern University, where he focused on Healthcare Enterprise Management and was a Zell Fellow in entrepreneurship.
Amit co-founded Cardiosense in 2020 and served as founding CEO through 2025, leading the company from inception through key clinical, regulatory, and product milestones. He negotiated exclusive technology and data licenses, raised ~$30M in funding, and led execution of nationwide, multi-center clinical studies that supported multiple FDA clearances for the company's devices and AI software.
Dr. Arezou Azar is a medical device executive with a proven track record of leading large-scale global programs across regulatory compliance, clinical AI development, and medical device commercialization. She holds a PhD in Biomedical Engineering (Machine Learning in Health), an MSc in Electrical Engineering (Signal and Image Processing), and a BSc in Computer Science, giving her a rare technical depth that spans AI, clinical science, and systems engineering.
Dr. Azar has launched multiple AI/ML products, FDA-cleared medical devices, and consumer health electronics across U.S. and global markets, with deep expertise in FDA regulatory pathways — including 510(k), De Novo, and Breakthrough Device Designation, and FDA TAP (Total Product Life Cycle Advisory Program) — as well as EU MDR, global regulations and international submissions. She has built and led cross-functional teams at enterprise scale, driving complex programs from clinical validation through global market authorization, and quality management systems. Her clinical expertise in AI medical device development spans algorithm validation, clinical study design, and evidence generation for SaMD products.
Her career includes serving as Global Head of Regulatory and Quality at Apple Health, where she led the FDA clearance and worldwide launch of Apple Watch’s first ECG feature — a landmark AI medical device launch at consumer scale. Prior to Cardiosense, Dr. Azar served as the Chief Compliance Officer at Cardiologs and has held leadership positions at Eko Devices, Google/Verily, Apple, and AliveCor, and earlier served as a Fellow at the FDA’s Center for Devices and Radiological Health (CDRH). At Cardiosense, she leads compliance and program management for Cardiosense’s FDA Breakthrough Designated cardiac AI platform, and other medical devices.
Dr. Etemadi serves as the medical director of Advanced Technologies at Northwestern Medicine and is a Research Assistant Professor in Anesthesiology and Biomedical Engineering at Northwestern University. He received his B.S (2008) and M.S. (2009) in Electrical Engineering from Stanford University, completed his Ph.D. (2013) at UC Berkeley, and received an M.D. (2016) from UCSF. His research during medical and graduate school has been recognized by awards including Forbes Magazine "30 Under 30 Scientists", CIMIT Prize for Primary Care Innovation, Bill and Melinda Gates Foundation Grand Challenges Winner, and Vodafone Americans Wireless Innovation Challenge.
As medical director of Advanced Technologies at Northwestern, Dr. Etemadi's team led the development and deployment of a system-wide artificial intelligence system that helps identify patients who have critical findings on radiology studies and ensures timely follow-up.
Careers
Cardiosense is a rapidly growing, venture-backed healthcare technology company redefining how heart disease is detected, monitored, and managed. We are developing novel wearable sensing technology and advanced AI driven algorithms that translate physiological signals into clinically actionable insights designed to improve patient outcomes and support the future of cardiovascular care.
Our team brings together experts across engineering, clinical research, biosignal analysis, operations, and medicine who are united by a shared mission to advance the next generation of cardiac monitoring and disease management. Built on more than a decade of clinical research and innovation, Cardiosense continues to collaborate with leading academic and healthcare institutions to deliver transformative healthcare technology.
We are looking for curious, collaborative individuals who thrive in fast paced environments and want to make a meaningful impact in healthcare innovation. Whether your expertise is in engineering, clinical, operations, product development, or business functions, you will have the opportunity to contribute directly to technology designed to improve lives.
Connect With Our Team
At Cardiosense, we are always looking for passionate and innovative individuals who want to make an impact in medtech and healthcare innovation. Explore our open positions or tell us a little about yourself, what excites you about Cardiosense, and the type of opportunities you are interested in. Share your background, interests, and resume to stay connected with future opportunities.
